Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma
- 358 Downloads
Hugo J.A. Adams: study design, article writing, final approval of the manuscript.
Thomas C. Kwee: study design, article writing, final approval of the manuscript.
Compliance with ethical standards
This work was financially supported by an Alpe d’HuZes/Dutch Cancer Society Bas Mulder Award for T.C.K. (grant number 5409). Data collection, data analysis, and interpretation of data, writing of the paper, and decision to submit were left to the authors’ discretion and were not influenced by Alpe d’HuZes/Dutch Cancer Society.
Conflict of interest
None (all authors).
- 1.Fallanca F, Alongi P, Incerti E, Gianolli L, Picchio M, Kayani I, et al. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville criteria (DC) and the international harmonization project criteria (IHPC). Eur J Nucl Med Mol Imaging. 2016. doi: 10.1007/s00259-016-3390-9.CrossRefGoogle Scholar
- 5.Nakayama H, Aisa Y, Ito C, Shimazaki K, Katsumata Y, Hayashi H, et al. Importance of histologic verification of positive positron emission tomography/computed tomography findings in the follow-up of patients with malignant lymphoma. Clin Lymphoma Myeloma Leuk. 2015;15:753–60. doi: 10.1016/j.clml.2015.07.636.CrossRefGoogle Scholar
- 9.Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42. doi: 10.1182/blood-2013-09-524108.CrossRefPubMedPubMedCentralGoogle Scholar